SEC Form 4 · accession 0001104659-16-100654
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ivan Bergstein
Officer — Chief Executive Officer · Director
Period of report
Feb 24, 2016
Accepted (ET)
Feb 26, 2016 · 8:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 24, 2016 | A | 178,083 | $0.00 | A | 1,851,665 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $4.12 | Feb 24, 2016 | A | 356,700 | A | Feb 24, 2017 | Feb 24, 2026 | Common Stock | 356,700 | 356,700 | D |
Explanation of responses
- F1The 178,083 restricted shares will vest in four installments as follows: 44,521 shares on February 24, 2017; 44,521 shares on February 24, 2018; 44,521 shares on February 24, 2019; and 44,520 shares on February 24, 2020.
- F2The 356,700 options will vest in four installments as follows: 89,175 shares on February 24, 2017; 89,175 shares on February 24, 2018; 89,175 shares on February 24, 2019; and 89,175 shares on February 24, 2020.